DARIOHEALTH CORP. (NASDAQ:DRIO) Files An 8-K Other Events
Item 8.01
Attached as Exhibit 99.1 to this Current Report on Form 8-K is an investor presentation which DarioHealth Corp., or the Company, has used in certain investor meetings with respect to its proposed offering. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.
(d) Exhibits.
| 99.1 | Investor Presentation |
DarioHealth Corp. Exhibit
EX-99.1 2 tv522107_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 DarioHealth Corp. Live Therapeutics for Better Life Forward Looking Statements. This presentation of DarioHealth Corp. (the “Company”) and statements of our managemen t contain or may contain forward – looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Statements which are not historical reflect our current expectations and projections about our future results,…
To view the full exhibit click here
About DARIOHEALTH CORP. (NASDAQ:DRIO)
DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter. The Dario product is a digital diabetes management solution utilizing its technology delivered through a software application available for iPhone or Android and cloud-based data services with a blood glucose monitoring system device. Dario allows users to record, analyze, transmit and store various data points, such as glucose level, insulin and carbohydrate intake. It markets the Dario Smart Diabetes Management Solution in the Netherlands and New Zealand.